ReviewHepatic medicine : evidence and research2012
Natural history and management of primary biliary cirrhosis.
Review in Hepatic medicine : evidence and research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Total bile acid to platelet ratio: A noninvasive index for predicting liver fibrosis in primary biliary cholangitis.Medicine · 2020Trial
- Folate deficiency correlates with severity of primary biliary cholangitis via modulating key regulatory genes.Frontiers in nutrition · 2026Article
- Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies.Turkish journal of medical sciences · 2022Article
- APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.Hepatology international · 2022Article
- Shear wave elastography and shear wave dispersion imaging in primary biliary cholangitis-a pilot study.Quantitative imaging in medicine and surgery · 2022Article
- Primary Biliary Cholangitis Overlap With Autoimmune Hepatitis? A Case Report.Journal of medical cases · 2021Article
- Anxiety and Depression in Patients with Primary Biliary Cholangitis: Current Insights and Impact on Quality of Life.Hepatic medicine : evidence and research · 2021Review
- Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia.International journal of public health · 2020Article
- Emerging therapies for PBC.Journal of gastroenterology · 2020Review
- Palmoplantar keratoderma as a presenting sign of primary biliary cirrhosis.JAAD case reports · 2018Article
- A brief review on prognostic models of primary biliary cholangitis.Hepatology international · 2017Review
- Ultrasound elastography: liver.Abdominal imaging · 2015Review
- Primary biliary cirrhosis is a generalized autoimmune epithelitis.International journal of molecular sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary biliary cirrhosis (PBC) is a chronic inflammatory autoimmune disease that mainly targets the cholangiocytes of the interlobular bile ducts in the liver. It is a rare disease with prevalence of less than one in 2000. Its prevalence in developing countries is increasing presumably because of growth in recognition and knowledge of the disease. PBC is thought to result from a combination of multiple genetic factors and superimposed environmental triggers. The contribution of the genetic predisposition is evidenced by familial clustering. Several risk factors, including exposure to infectious agents and chemical xenobiotics, have been suggested. Common symptoms of the disease are fatigue and pruritus, but most patients are asymptomatic at first presentation. The prognosis of PBC has improved because of early diagnosis and use of ursodeoxycholic acid, the only established medical treatment for this disorder. When administered at adequate doses of 13-15 mg/kg/day, up to two out of three patients with PBC may have a normal life expectancy without additional therapeutic measures. However, some patients do not respond adequately to ursodeoxycholic acid and might need alternative therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.